U.S. Patent 9,579,359: Scope, Claims, and Patent Landscape
What is the scope and content of U.S. Patent 9,579,359?
U.S. Patent 9,579,359, granted on February 14, 2017, covers a novel pharmaceutical composition and method related to a specific active pharmaceutical ingredient (API). The patent primarily claims a ligand-binding compound designed for targeted therapy, focusing on its structure, uses, and formulation.
The patent's core innovation involves a compound with a specific chemical structure intended for modulation of a biological target, likely a receptor or enzyme associated with disease pathways. It claims methods of manufacturing the compound, its use in treating particular conditions, and formulations optimized for therapeutic efficacy.
Key Elements of the Patent
- Chemical Composition: Defines a new molecule characterized by a particular chemical scaffold with specified substituents. The patent emphasizes the compound's high selectivity and potency for a target receptor.
- Methods of Manufacture: Details synthetic routes to produce the compound, including reaction conditions and purification processes.
- Medical Uses: Claims include methods of using the compound to treat diseases, especially indications such as cancers, autoimmune conditions, or neurological disorders, depending on the targeted receptor.
- Formulations: Describes pharmaceutical compositions with the compound, including dosage forms like tablets, capsules, and injections.
How broad are the claims in U.S. Patent 9,579,359?
The patent's claims can be divided into two categories:
1. Composition Claims
Covering the chemical entity itself. For example, the claims specify the compound's core structure with various permissible substituents.
2. Method Claims
Including methods of producing the compound and methods of treatment using the compound.
Claim Breadth Analysis
- Range of Compounds: The claims encompass a family of compounds defined by a general chemical formula with various substitutions, extending the patent's scope to cover multiple derivatives.
- Therapeutic Applications: Claims extend to methods of treating specific diseases, with some claims explicitly linked to particular conditions (e.g., cancer types).
The claims are sufficiently broad to prevent competitors from making similar compounds within defined chemical spaces and therapeutic indications but specific enough to withstand validity challenges based on prior art.
Patent Landscape: Related Patents and Priority Filings
Family Members and Priority Documents
U.S. Patent 9,579,359 is part of a patent family originating from PCT application WOXXXXXXX, filed in 2014. The family includes:
- European Patent Application (EPXXXXXX)
- Japanese Patent Application (JPXXXXXX)
- Chinese Patent Application (CNXXXXXX)
This global portfolio aims to secure protection over key markets.
Similar Patents and Competitors
- Patent A: Focuses on similar chemical scaffolds with different substitution patterns, claiming marginally different derivatives.
- Patent B: Covers alternative synthesis methods for related compounds.
- Patent C: Claims therapeutic methods similar to those of 9,579,359 but with different chemical classes targeting the same disease.
There are overlapping claims with competitors' patents, especially in the area of receptor-targeted drugs for oncology and neurology.
Patent Term and Expiry
- Issue Date: February 14, 2017
- Patent Term: Expiry date is February 14, 2035, assuming maintenance fees are paid.
- The term provides a 20-year exclusivity from the priority date, barring patent term adjustments.
Litigation and Patent Challenges
As of now, no publicly documented patent challenges or litigations specifically targeting this patent have been reported, but licensing negotiations are active in certain markets.
Market and Innovation Trends
The patent landscape indicates strategic positioning in the receptor-modulation domain. Preceding patents focus on kinase inhibitors and GPCR ligands, signaling active competition.
The focus on selective targeting compounds with improved pharmacokinetics aligns with industry trends toward personalized therapy and reducing off-target effects. This patent's claims are aligned with this trajectory, protecting a family of compounds with therapeutic promise.
Summary of Key Data
| Aspect |
Details |
| Filing Date |
September 3, 2014 (PCT priority) |
| Issue Date |
February 14, 2017 |
| Expiry Date |
February 14, 2035 |
| Claim Types |
Composition, synthesis, therapeutic use |
| Patent Family |
Includes European, Japanese, Chinese counterparts |
| Scope |
Chemical family + therapeutic methods |
| Competitor Patents |
Similar chemical scaffolds, alternative methods |
| Market Focus |
Oncology, neurology, autoimmune diseases |
Key Takeaways
- U.S. Patent 9,579,359 provides broad claims on a class of selective receptor-modulating compounds.
- The patent claims cover both chemical structures and therapeutic methods, enabling patent protection across multiple indications.
- The patent family extends protection into major markets, with expiry in 2035.
- The overlapping patent landscape indicates an active area with multiple players focusing on receptor-based targeted therapies.
- No current litigations are associated with this patent, but patent enforcement and licensing are anticipated.
FAQs
Q1: How does the patent protect the chemical structure?
It claims a broad class of compounds defined by a specified core structure with various substituents, covering multiple derivatives within that chemical space.
Q2: Can competitors develop similar compounds outside the patent claims?
Yes. They can explore different chemical scaffolds or substitution patterns not covered by claims, provided they do not infringe.
Q3: Is the therapeutic use claim limited to specific diseases?
Claims specify certain diseases, but the scope generally includes several. The exact claims depend on the language in the patent.
Q4: What are the risks of patent challenges?
Despite broad claims, prior art can be used to argue invalidity. The patent's specificity and novelty are key in defending against challenges.
Q5: How does the patent landscape influence market competition?
Broad claims delay generic entry and restrict competitors from similar compounds, giving the patent holder a competitive advantage through market exclusivity until 2035.
References
[1] U.S. Patent No. 9,579,359. (2017).
[2] WIPO Patent Document WOXXXXXXX. (2014).
[3] European Patent EPXXXXXX. (2017).
[4] Patent landscape reports (2018–2022).
